Recently, the FDA approved axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent. The approval was based on results from ZUMA-5, a phase 2 trial in which axicabtagene ciloleucel demonstrated a high rate of efficacy. In this interview, one of the study investigators, Julio Chavez, MD, of the Moff...

According to researchers, the disparity in cancer mortality rates between older patients with both human immunodeficiency virus (HIV) and cancer and older patients who have cancer but not HIV is due to more than the suboptimal cancer treatment given to those with HIV. It has previously been established that patients with both HIV and cancer have higher rates of cancer-specific mortality in comparison to other patients with cancer, yet the cause of this discrepancy has not been fully explained. "...

A new study conducted by Moffitt Cancer Center in conjunction with Huntsman Cancer Institute and Harvard T.H. Chan School of Public Health found that women who take low-dose aspirin daily are at lower risk of developing ovarian cancer. The findings, published online by JAMA Oncology, also show that women who take at least 10 tablets per week of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen over many years are at an increased risk of developing ovarian can...